Walleye Capital’s Immuneering IMRX Stock Holding History

Walleye Capital’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,625	Closed	-$95K	–	2529
2022 Q1	$95K	Buy	+14,625	New	+$140K	﹤0.01%	1759

Other funds holding IMRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BSW

Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's IMRX Position: Q2 2022 in Review

Walleye Capital sold out of Immuneering (IMRX) in Q2 2022, closing a stake of 14,625 shares — an estimated $95K sold.

Walleye Capital first reported a position in IMRX in Q1 2022 and held it in 1 quarter. The position peaked at $95K in Q1 2022. 37 funds tracked by Wall St. Rank hold IMRX as of Q2 2022.

Walleye Capital reported no remaining Immuneering position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 14,625 Immuneering shares in Q2 2022, an estimated $95K.
Walleye Capital first reported a position in Immuneering in Q1 2022 and held it in 1 quarter.
Walleye Capital's Immuneering position peaked at $95K in Q1 2022.
37 funds tracked by Wall St. Rank held Immuneering as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.